![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 10
Zeitschriftenartikel
Braulke, Friederike; Zettl, Florian; Ziepert, Marita; Viardot, Andreas; Kahl, Christoph; Prange-Krex, Gabriele; Korfel, Agnieszka; Dreyling, Martin; Bott, Alexander; Wedding, Ulrich; Reichert, Dietmar; de Wit, Maike; Hartmann, Frank; Poeschel, Viola; Schmitz, Norbert; Witzens-Harig, Mathias; Klapper, Wolfram; Rosenwald, Andreas; Wulf, Gerald; Altmann, Bettina und Trumper, Lorenz
(2022):
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.
In: Hemasphere, Bd. 6, Nr. 12, e808
Hess, Georg; Huettmann, Andreas; Witzens-Harig, Mathias; Dreyling, Martin H.; Keller, Ulrich; Marks, Reinhard; Ernst, Thomas; Pott, Christiane; Viardot, Andreas; Frontzek, Fabian; Trautmann, Marcel; Ruckes, Christian; Deuster, Oliver; Rosenwald, Andreas; Theobald, Matthias und Lenz, Georg
(2022):
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
In: British Journal of Haematology, Bd. 198, Nr. 3: S. 482-491
Witzens-Harig, Mathias; Viardot, Andreas; Keller, Ulrich; Wosniok, Julia; Deuster, Oliver; Klemmer, Jennifer; Geueke, Anne-Marie; Meissner, Julia; Ho, Anthony D.; Atta, Johannes; Marks, Reinhard; La Rosee, Paul; Buske, Christian; Dreyling, Martin H. und Hess, Georg
(2021):
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial.
In: Hemasphere, Bd. 5, Nr. 10, e636
Hess, Georg; Wagner, Karola; Keller, Ulrich; La Rosee, Paul; Atta, Johannes; Hübel, Kai; Lerchenmueller, Christian; Schoendube, Daniel; Witzens-Harig, Mathias; Ruckes, Christian; Medler, Christoph; Oordt, Christina van; Klapper, Wolfram; Theobald, Matthias und Dreyling, Martin
(2020):
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma.
In: Hemasphere, Bd. 4, Nr. 3, e398
König, Laila; Dreyling, Martin; Duerig, Jan; Engelhard, Marianne; Hohloch, Karin; Viardot, Andreas; Witzens-Harig, Mathias; Kieser, Meinhard; Klapper, Wolfram; Pott, Christiane und Herfarth, Klaus
(2019):
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro)-GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
In: Trials, Bd. 20, Nr. 1, 544
Kriegsmann, Katharina; Kriegsmann, Mark; Bergwelt-Baildon, Michael von; Cremer, Martin und Witzens-Harig, Mathias
(2018):
NKT cells - New players in CAR cell immunotherapy?
In: European Journal of Haematology, Bd. 101, Nr. 6: S. 750-757
Hess, Georg; Rule, Simon; Jurczak, Wojciech; Jerkeman, Mats; Silva, Rodrigo Santucci; Rusconi, Chiara; Caballero, Dolores; Joao, Cristina; Witzens-Harig, Mathias; Bence-Bruckler, Isabelle; Cho, Seok-Goo; Zhou, Wenjiong; Goldberg, Jenna D.; Trambitas, Cristina; Enny, Christopher; Vermeulen, Jessica; Traina, Shana; Chiou, Chiun-Fang; Diels, Joris und Dreyling, Martin
(2017):
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
In: Leukemia & Lymphoma, Bd. 58, Nr. 12: S. 2824-2832
Dreyling, Martin; Jurczak, Wojciech; Jerkeman, Mats; Santucci Silva, Rodrigo; Rusconi, Chiara; Trneny, Marek; Offner, Fritz; Caballero, Dolores; Joao, Cristina; Witzens-Harig, Mathias; Hess, Georg; Bence-Bruckler, Isabelle; Cho, Seok-Goo; Bothos, John; Goldberg, Jenna D.; Enny, Christopher; Traina, Shana; Balasubramanian, Sriram; Bandyopadhyay, Nibedita; Sun, Steven; Vermeulen, Jessica; Rizo, Aleksandra und Rule, Simon
(2016):
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study.
In: Lancet, Bd. 387, Nr. 10020: S. 770-778
Witzens-Harig, Mathias; Memmer, Marie Luise; Dreyling, Martin und Hess, Georg
(2013):
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
In: BMC Cancer
13:308
[PDF, 223kB]
Witzens-Harig, Mathias; Hensel, Manfred; Unterhalt, Michael und Herfarth, Klaus
(2011):
Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial.
In: BMC Cancer
11:87
[PDF, 278kB]